Jane Street Group LLC Sells 183,577 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Jane Street Group LLC decreased its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 41.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 262,608 shares of the biopharmaceutical company’s stock after selling 183,577 shares during the period. Jane Street Group LLC’s holdings in Dynavax Technologies were worth $3,354,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Dynavax Technologies during the fourth quarter valued at $990,000. Palumbo Wealth Management LLC bought a new position in Dynavax Technologies during the 4th quarter valued at about $275,000. Barclays PLC boosted its position in Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after buying an additional 175,118 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its position in Dynavax Technologies by 97.6% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company’s stock valued at $3,964,000 after buying an additional 153,302 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in Dynavax Technologies during the fourth quarter worth about $883,000. 96.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. JMP Securities cut their price objective on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 6th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, The Goldman Sachs Group decreased their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $24.00.

Dynavax Technologies Stock Up 4.7%

NASDAQ:DVAX opened at $9.85 on Tuesday. The company has a market cap of $1.18 billion, a price-to-earnings ratio of 54.72 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock’s fifty day moving average price is $12.16 and its two-hundred day moving average price is $12.57. Dynavax Technologies Co. has a 52-week low of $9.28 and a 52-week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). The firm had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.